2023 Current Fiscal Year Report: Tick-Borne Disease Working Group

Report Run Date: 04/26/2024 11:36:58 AM

1. Department or Agency		2. Fis	2. Fiscal Year		
Department of Health and Human Services			2023	2023	
3. Committee or Subcommittee		3b. G No.	3b. GSA Committee No.		
Tick-Borne Disease Wo	rking Grou	ıp	2619		
4. Is this New During 5	. Current	6. Expe	cted	7. Expected	
Fiscal Year? C	harter	Renewa	l Date	Term Date	
No 0	8/10/2021	08/10/20)23	12/13/2022	
8a. Was Terminated	8b. Sj	pecific		8c. Actual	
During FiscalYear?	Termi	ination A	uthority	/ Term Date	
Yes		on 2062 o Century C		12/13/2022 t	
9. Agency Recommendation for Next FiscalYear		_egislatic rminate?	-	10b. Legislation Pending?	
Terminate	Yes			Not Applicable	
11. Establishment Aut		atutory (C	onaress		
	13.	14.	ongress	Orealed)	
12. Specific Establishment Author	Effecti		nmitee De	14c. Presidential?	
Section 2062 of the 21s Century Cures Act	t 12/13/2	2016 Cor	ntinuina	No	
15. Description of Committee Scientific Technical Program					
15. Description of Con	nmittee S	cientific T	Ū		
15. Description of Con Advisory Board	nmittee S	cientific T	Ū		
-		cientific T	Ū		
Advisory Board	Reports 1	cientific T	Ū		
Advisory Board 16a. Total Number of F 16b. Report Report Title	Reports 1		echnica		
Advisory Board 16a. Total Number of F 16b. Report Date	Reports 1 Disease W t to Congr	/orking G ess	echnica		
Advisory Board 16a. Total Number of F 16b. Report Date 12/13/2022 Tick-Borne 2022 Report Number of Committee 17a. 3 17b. Closed 0	Reports 1 Disease W t to Congr Reports L	/orking G ess ₋isted: 1	echnica		
Advisory Board 16a. Total Number of F 16b. Report Date 12/13/2022 Tick-Borne 2022 Report Number of Committee	Reports 1 Disease W t to Congr Reports L	/orking G ess ₋isted: 1	echnica	l Program	

For this meeting, the TBDWG (1) reviewed the final draft of chapters for the report and (2) further discussed plans for developing the next report to the HHS Secretary and 10/04/2022 - 10/05/2022
Congress on federal tick-borne activities and research, taking into consideration the 2018
and 2020 report.
For this meeting, the TBDWG will review and vote upon the third and final Report to10/24/2022 - 10/25/2022Congress and the HHS Secretary.
The TBDWG met for the final time to take a final vote on chapters of the 2022 Report to 11/21/2022 - 11/21/2022 Congress.

Number of Committee Meetings Listed: 3

Number of Committee meetings Listed: 5				
	Current FY Next FY			
18a(1). Personnel Pmts to				
Non-Federal Members	\$0.00 \$0.00			
18a(2). Personnel Pmts to	¢40.007.04¢0.00			
Federal Members	\$10,337.04\$0.00			
18a(3). Personnel Pmts to	\$142,376.00\$0.00			
Federal Staff	φ142,370.00φ0.00			
18a(4). Personnel Pmts to	\$0.00 \$0.00			
Non-Member Consultants	φ0.00 φ0.00			
18b(1). Travel and Per Diem	\$0.00 \$0.00			
to Non-Federal Members	φ0.00 φ0.00			
18b(2). Travel and Per Diem	\$0.00 \$0.00			
to Federal Members	φ0.00 φ0.00			
18b(3). Travel and Per Diem	\$0.00 \$0.00			
to Federal Staff	ψ0.00 ψ0.00			
18b(4). Travel and Per Diem	\$0.00 \$0.00			
to Non-member Consultants	ψ0.00 ψ0.00			
18c. Other(rents,user				
charges, graphics, printing,	\$161,220.00\$0.00			
mail, etc.)				
18d. Total	\$313,933.04\$0.00			
19. Federal Staff Support	2.00 0.00			
Years (FTE)	2.00 0.00			

20a. How does the Committee accomplish its purpose?

The Working Group is charged to review ongoing

activities and research related to tick-borne diseases conducted by HHS and other federal agencies, identify gaps in research and advances made, and provide a report to Congress and the HHS Secretary on its finding and recommendations every two years. The Working Group is also charged with soliciting input from States, localities, and nongovernmental entities, including organizations representing patients, health care providers, researchers, and industry. Subcommittees established by the Working Group research topic areas determined relevant to its charge and provide reports, including action items, for discussion and consideration by the Working Group for the biannual reports. The 2022 Report was delivered to Congress and the HHS Secretary in January 2023 and also posted on the HHS website for public access.

20b. How does the Committee balance its membership?

The Working Group comprises 14 members seven federal members and seven public members. Federal members are required to consist of one or more representatives from the following HHS organizational components: Office of the Assistant Secretary for Health, Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, and such other agencies and offices of HHS and other individuals as the Secretary determines appropriate and beneficial to the functioning of the Working Group. Other federal members represent the Centers for Medicare and Medicaid Services, Department of Defense, and the United States Department of Agriculture. Public members are required to represent the following categories: physicians and other health care providers with experience in diagnosing and treating tick-borne

diseases; scientists or researchers with expertise; patients and their family members; and members of nonprofit organizations that advocate for patients with respect to tick-borne diseases.

20c. How frequent and relevant are the Committee Meetings?

The Working Group is required to meet not less than two times a year. Three meetings were held in FY23 and focused on topics and issues that supported development of the 2022 report to the HHS Secretary and Congress, taking into consideration the 2018 and 2020 report.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The 21st Century Cures Act (Public Law 114-255), Section 2062 Tick-Borne Diseases, authorized the HHS Secretary to establish a Tick-Borne Disease Working Group. In general, the Working Group is to provide expertise and to review all efforts within HHS related to all tick-borne diseases and examine agency research priorities in order to help ensure interagency coordination and minimize overlap. Every two years, the Working Group is required to submit a report to Congress and the HHS Secretary on its findings and any recommendations for improving the federal response to tick-borne diseases. The final report was delivered to Congress in January 2023.

20e. Why is it necessary to close and/or partially closed committee meetings? N/A

21. Remarks

The authorizing legislation outlined a committee termination date of 12/13/2022 and in accordance with the legislation the committee was terminated

on that date.

Designated Federal Officer

James J Berger Senior Advisor for Blood and Tissue Policy, Office of Infectious Disease and HIV/AIDS Policy

HIV/AIDS FUICY				
Committee Members	Start	End	Occupation	Member Designation
Beard, Ben	12/11/2017	12/13/2022	CDC	Regular Government Employee (RGE) Member
Bunnell, Rebecca	06/04/2019	12/13/2022	CMS	Regular Government Employee (RGE) Member
Dixon, Dennis	12/11/2017	12/13/2022	NIH	Regular Government Employee (RGE) Member
Embers, Monica	08/26/2021	12/13/2022	Associate Professor and Director, Vector borne Disease Research	Special Government Employee (SGE) Member
Goodreau, Holiday	08/26/2021	12/13/2022	Executive Director, LivLyme Foundation	Special Government Employee (SGE) Member
Hu, Linden	08/26/2021	12/13/2022	Professor of Microbiology and Medicine, Vice Dean for Research, Tufts University School of Medicine	Special Government Employee (SGE) Member
Maloney, Elizabeth	08/26/2021	12/13/2022	Physician	Special Government Employee (SGE) Member
Miller, Robert	08/26/2021	12/13/2022	USDA	Regular Government Employee (RGE) Member
Myers, Todd	08/26/2021	12/13/2022	FDA	Regular Government Employee (RGE) Member

Platt, Jennifer	08/26/2021	12/13/2022	Co-founder, Tick-Borne Conditions United	Special Government Employee (SGE) Member
Sood, Sunil	08/26/2021	12/13/2022	Infectious Disease Physician	Special Government Employee (SGE) Member
Stafford, Kirby	08/26/2021	12/13/2022	Chief Scientist and State Entomologist	Special Government Employee (SGE) Member
States, Leith	06/04/2019	12/13/2022	OASH	Regular Government Employee (RGE) Member
Zollner, Gabriela	08/26/2021	12/13/2022	DoD	Regular Government Employee (RGE) Member

Number of Committee Members Listed: 14

Narrative Description

What are the most significant program outcomes associated with this committee?

	Checked if	
	Applies	
Improvements to health or safety		✓
Trust in government		✓
Major policy changes		✓
Advance in scientific research		✓
Effective grant making		
Improved service delivery		✓
Increased customer satisfaction		~
Implementation of laws or regulatory		
requirements		
Other		

Outcome Comments

What are the cost savings associated with this committee?

	Checked if Applies
None	
Unable to Determine	\checkmark
Under \$100,000	
\$100,000 - \$500,000	
\$500,001 - \$1,000,000	
\$1,000,001 - \$5,000,000	
\$5,000,001 - \$10,000,000	
Over \$10,000,000	
Cost Savings Other	

Cost Savings Comments

Cost savings dependent on action taken on recommendations

What is the approximate <u>Number</u> of recommendations produced by this committee for the life of the committee?

Number of Recommendations Comments

The 2018 Report to the HHS Secretary and Congress included 28 recommendations, the 2020 Report included 27 recommendations, and the 2022 Report included 20 recommendations.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Fully</u> implemented by the agency?

% of Recommendations Fully Implemented Comments

Many of the recommendations require long-term action which cannot be accomplished in a fiscal year.

What is the approximate <u>Percentage</u> of these recommendations that have been or will be <u>Partially</u> implemented by the agency?

15%

% of Recommendations Partially Implemented Comments

Many of the recommendations require long-term action which cannot be accomplished in a fiscal year.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes 🗹 No 🗌 Not Applicable 🗌

Agency Feedback Comments

HHS has the responsibility of ensuring the conduct of or support for epidemiological, basic, translational, and clinical research related to vector-borne diseases, including tick-borne diseases. Section 2062 of the 21st Century Cures Act mandated the Secretary of HHS establish the Tick-Borne Disease Working Group to review activities and research related to tick-borne diseases conducted by HHS and other federal agencies and provide a report to Congress and the HHS Secretary on its finding and recommendations every two years. The Working Group terminated in December 2022, six years after the date of enactment of the authorizing legislation. The public can view information on this Working Group at https://www.hhs.gov/ash/advisory-committees/tickbornedisease/index.html.

What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	
Reallocated resources	
Issued new regulation	
Proposed legislation	
Approved grants or other payments	
Other	

Action Comments

Not applicable

Is the Committee engaged in the review of applications for grants? No

Grant Review Comments

Not Applicable

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	✓
Online Agency Web Site	\checkmark
Online Committee Web Site	\checkmark
Online GSA FACA Web Site	\checkmark
Publications	\checkmark
Other	

Access Comments

N/A